The results provide a better understanding for investigating therapeutic approaches for other tumor entities with higher rates of KRAS mutation, e.g., pancreatic cancer and colorectal cancer, as well as in tumor entities with the hyperactivation of the PI3K/Akt pathway, which is of particular importance. This evidence concerns the gene KRAS and neoplasm.